Remdesivir, among the treatments used for the United States President Donald Trump's COVID-19 infection, does not reportedly reduce deaths among COVID-19 patients. 

The antiviral drug was compared with standard care, according to the results of a large, international trial.

According to the World Health Organization (WHO), in a statement on Friday, along with remdesivir, hydroxychloroquine, interferon, and lopinavir/ritonavir produce a small or no result in the treatment for the novel coronavirus. 

"In just six months, the world's largest randomized control trial on COVID-19 therapeutics has generated conclusive evidence on the effectiveness of repurposed drugs for the treatment of COVID-19," reported Tass.

The global agency added, "Interim results from the Solidarity Therapeutics Trial, coordinated by the World Health Organization, indicate that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients."

WHO's declaration is in contrast with an initial study that made the medicine a standard of care in the United States and many other countries. The results declared on Friday do not cancel out the previous ones. 

The WHO study was also not as meticulous as the initial study led by the United States National Institutes of Health, reported Listen Up Yall.

In May, the Food and Drug Administration (FDA) permitted remdesivir to be used as emergency COVID-19 treatment after a large clinical trial suggesting that the drug diminishes the duration for COVID-19 patients' hospitalization in contrast to placebo treatment. 

Remdesivir, as of August, has been authorized to be administered to COVID-19 patients, not only for those on supplemental oxygen, reported Newsbreak.

Also Read: Antibody Promises COVID-19 Treatment, But Not Cure

Hydroxychloroquine, interferon, and lopinavir/ritonavir have initially been advised as potential COVID-19 treatments. 

The WHO trial was held for six months, wherein the majority of the treatments being studied had been ruled out.

The remdisivir drug taken by President Trump was manufactured by the United States biotech company Gilead.

In contrast to a U.S. trial that had previously displayed it diminished the length of hospitalization, the gold-standard Solidarity WHO trial was based on a larger sample. 

Three thousand people who were administered the drug compared with the same number who were not, displayed the drug had little effect on fatalities in 28 days.

The antiviral drug has been specified as standard-of-care in the U.S. and has been approved for use in the U.K. and EU. Supplies of remdesivir have been limited. 

The European Medicines Agency is currently evaluating whether being administered remdesivir results in kidney problems, as reported by a number of patients.

The trial, sponsored by WHO, was posted on October 15 on database medRxiv. The study is yet to be peer-reviewed and involved over 11,200 participants from 30 countries.

An estimated 4,100 patients were the comparison group that received no drug treatments. The other participants received one of four drugs or a merge of multiple medications.

The study oversaw the effects of such treatments on overall initiation of ventilation, mortality, and duration of hospitalization of patients.

Related Article: Trump: COVID-19 Negative, Not Infectious - White House Doctors